Home / Content / B2B Connect / Chemicals / Daiichi Sankyo shuts down Indian R&D unit

Daiichi Sankyo shuts down Indian R&D unit

The unit mainly conducted drug discovery research targeting infectious diseases & inflammation

premium

Daiichi Sankyo’s R&D unit in India

Last Updated : Jan 17 2017 | 11:20 AM IST

Japanese pharmaceutical company Daiichi Sankyo Company Limited has decided to close its Gurgaon (Haryana) based research subsidiary, Daiichi Sankyo India Pharma Private Limited (DSIN), to increase its R&D productivity.

Daiichi Sankyo is reviewing its global R&D system with the aim of decreasing R&D operations costs and redistributing resources to the further development of its R&D pipeline.

DSIN presently employs approximately 170 people, mainly engaged in conducting drug discovery research targeting infectious diseases and inflammation. Following its closure, the DSIN R&D pipeline - including research themes selected by the Global Health Innovative Technology Fund (GHIT Fund) - will be transferred to Daiichi Sankyo’s R&D division.

Established in 2007, DSIN has been contributing to Daiichi Sankyo’s global R&D activity. The unit focused on a small molecule drug discovery research in the areas of infectious and autoimmune diseases.